Diamond Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Diamond Therapeutics's estimated annual revenue is currently $904.5k per year.
- Diamond Therapeutics's estimated revenue per employee is $100,500
Employee Data
- Diamond Therapeutics has 9 Employees.
- Diamond Therapeutics grew their employee count by -18% last year.
Diamond Therapeutics's People
| Name | Title | Email/Phone |
|---|
Diamond Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $18.5M | 92 | -1% | N/A | N/A |
#2 | $14.3M | 71 | 6% | N/A | N/A |
#3 | $36M | 179 | 8% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $17.9M | 93 | 3% | $192.2M | N/A |
#6 | $64.9M | 323 | 4% | N/A | N/A |
#7 | $0.5M | 5 | -55% | N/A | N/A |
#8 | $6.8M | 34 | -41% | N/A | N/A |
#9 | $19.5M | 97 | 23% | N/A | N/A |
#10 | $2.5M | 25 | 19% | N/A | N/A |
What Is Diamond Therapeutics?
The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds.Our mission is to unlock it.We're developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines that have the potential to deliver greater impact than current first-line treatments.Our first clinical program is focused on accessible psilocybin-based drugs that deliver rapid therapeutic outcomes without perceptual side effects. By eliminating the side effects, this intervention can be administered to a broad cohort of patients.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$904.5k
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Toronto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 9 | 13% | $53M |
#2 | $0.9M | 9 | -18% | N/A |
#3 | $0.7M | 9 | N/A | N/A |
#4 | $0.1M | 9 | -18% | $1.3M |
#5 | $0.7M | 9 | N/A | N/A |